OBJECTIVE: The revised Bethesda Guidelines were published to improve the efficiency of recognizing Lynch syndrome (LS) by identifying LS-related malignancies that should be analyzed for microsatellite instability (MSI). The aim of this study was to evaluate whether MSI analysis was performed in colorectal cancer patients at risk for LS according to the revised Bethesda Guidelines. MATERIAL AND METHODS: Patients diagnosed with colorectal cancer in 11 Dutch hospitals in 2005 and 2006 were selected from a regional database. The patients were included in the study if they met any of the following criteria; 1) diagnosed with colorectal cancer <50 years, 2) a second LS-associated tumor prior to the diagnosis of colorectal cancer in 2005/2006, and 3) colorectal cancer <60 years with a tumor displaying mucinous or signet-ring differentiation or medullary growth pattern. RESULTS: Of 1905 colorectal cancer patients, 169 met at least one of the inclusion criteria. MSI analysis had been performed in 23 (14%) of the 169 tumors. MSI status had been determined in 18 of 80 included patients aged <50 years, in 4 of 70 patients with a second LS-related tumor, and in 3 of 41 patients aged <60 years with high-risk pathology features. CONCLUSIONS: There is marked underutilization of MSI analysis in patients at risk for LS. As a result LS might be underdiagnosed both in patients with colorectal cancer and in their relatives.
OBJECTIVE: The revised Bethesda Guidelines were published to improve the efficiency of recognizing Lynch syndrome (LS) by identifying LS-related malignancies that should be analyzed for microsatellite instability (MSI). The aim of this study was to evaluate whether MSI analysis was performed in colorectal cancerpatients at risk for LS according to the revised Bethesda Guidelines. MATERIAL AND METHODS:Patients diagnosed with colorectal cancer in 11 Dutch hospitals in 2005 and 2006 were selected from a regional database. The patients were included in the study if they met any of the following criteria; 1) diagnosed with colorectal cancer <50 years, 2) a second LS-associated tumor prior to the diagnosis of colorectal cancer in 2005/2006, and 3) colorectal cancer <60 years with a tumor displaying mucinous or signet-ring differentiation or medullary growth pattern. RESULTS: Of 1905 colorectal cancerpatients, 169 met at least one of the inclusion criteria. MSI analysis had been performed in 23 (14%) of the 169 tumors. MSI status had been determined in 18 of 80 included patients aged <50 years, in 4 of 70 patients with a second LS-related tumor, and in 3 of 41 patients aged <60 years with high-risk pathology features. CONCLUSIONS: There is marked underutilization of MSI analysis in patients at risk for LS. As a result LS might be underdiagnosed both in patients with colorectal cancer and in their relatives.
Authors: Paul G van Putten; Margot G F van Lier; Mariska Hage; Katharina Biermann; Reinier H van Rijssel; Pieter J Westenend; Hans Morreau; Ewout W Steyerberg; Winand N M Dinjens; Ernst J Kuipers; Monique E van Leerdam; J Han van Krieken Journal: Fam Cancer Date: 2014-09 Impact factor: 2.375
Authors: Jessica Ezzell Hunter; Kathleen A Arnold; Jennifer E Cook; Jamilyn Zepp; Marian J Gilmore; Alan F Rope; James V Davis; Kellene M Bergen; Elizabeth Esterberg; Kristin R Muessig; Susan K Peterson; Sapna Syngal; Louise Acheson; Georgia Wiesner; Jacob Reiss; Katrina A B Goddard Journal: Fam Cancer Date: 2017-07 Impact factor: 2.375
Authors: Elizabeth V Clarke; Kristin R Muessig; Jamilyn Zepp; Jessica E Hunter; Sapna Syngal; Louise S Acheson; Georgia L Wiesner; Susan K Peterson; Kellene M Bergen; Elizabeth Shuster; James V Davis; Jennifer L Schneider; Tia L Kauffman; Marian J Gilmore; Jacob A Reiss; Alan F Rope; Jennifer E Cook; Katrina A B Goddard Journal: Fam Cancer Date: 2019-07 Impact factor: 2.375
Authors: Brandie Heald; Thomas Plesec; Xiuli Liu; Rish Pai; Deepa Patil; Jessica Moline; Richard R Sharp; Carol A Burke; Matthew F Kalady; James Church; Charis Eng Journal: J Clin Oncol Date: 2013-02-11 Impact factor: 44.544
Authors: Talha Shaikh; Elizabeth A Handorf; Joshua E Meyer; Michael J Hall; Nestor F Esnaola Journal: JAMA Oncol Date: 2018-02-08 Impact factor: 31.777
Authors: Jessica Ezzell Hunter; Jamilyn M Zepp; Mari J Gilmore; James V Davis; Elizabeth J Esterberg; Kristin R Muessig; Susan K Peterson; Sapna Syngal; Louise S Acheson; Georgia L Wiesner; Jacob A Reiss; Katrina A B Goddard Journal: Cancer Date: 2015-06-02 Impact factor: 6.860
Authors: Celine H M Leenen; Anne Goverde; Esther W de Bekker-Grob; Anja Wagner; Margot G F van Lier; Manon C W Spaander; Marco J Bruno; Carli M Tops; Ans M W van den Ouweland; Hendrikus J Dubbink; Ernst J Kuipers; Winand N M Dinjens; Monique E van Leerdam; Ewout W Steyerberg Journal: Genet Med Date: 2016-03-03 Impact factor: 8.822
Authors: Deanna S Cross; Alanna Kulchak Rahm; Tia L Kauffman; Jennifer Webster; Anh Quynh Le; Heather Spencer Feigelson; Gwen Alexander; Paul Meier; Adedayo A Onitilo; Pamala A Pawloski; Andrew E Williams; Stacey Honda; Yeehwa Daida; Catherine A McCarty; Katrina A B Goddard Journal: Genet Med Date: 2013-05-02 Impact factor: 8.822
Authors: Margot G F van Lier; Anja Wagner; Monique E van Leerdam; Katharina Biermann; Ernst J Kuipers; Ewout W Steyerberg; Hendrikus Jan Dubbink; Winand N M Dinjens Journal: J Cell Mol Med Date: 2009-11-19 Impact factor: 5.310